In This Article:
MALAKOFF, France, February 07, 2025--(BUSINESS WIRE)--Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy for the treatment of varicose veins, reports on its 2024 activities.
Theraclion announced in its press release of January 6, 2025, the continuation of the strategic refocusing on the varicose veins market and confirmed its decision to no longer market its Echopulse machines intended to treat the thyroid in the near future. The company indicated on this occasion that it was taking back the old generation of Echopulse machines initially intended for the Chinese market, an operation resulting in the issuance by Theraclion of a credit note to the China joint venture of €680,000, to limit the latter's loss. The company has adjusted the half-year accounts to reflect the impact of this described operation and is publishing its adjusted results for the first half of 2024.
First half 2024 results before and after adjustment
| 30/06/2024 | 30/06/2024 | 30/06/2023 | ||
| In €K | Initial | Adjusted | Var. % | |
| Turnover | 442 | -239 | 981 | |
| from equipment sales | 108 | 108 | 597 | -82% |
| from sales of consumables | 287 | 287 | 314 | -9% |
| from sales of services | 46 | 46 | 69 | -33% |
| Credit note to JV China | -680 | |||
| Grants | 138 | 138 | 0 | |
| Other products | 38 | 38 | 0 | |
| Reversal of depreciation and provisions | 11 | 11 | 0 | |
| Total operating income | 628 | -51 | 981 | -105% |
| Cost of goods sold | 170 | -231 | 532 | -143% |
| Gross margin | 271 | -7 | 449 | -102% |
| % Gross margin | 61% | -3% | 45% | |
| Other Purchases of Goods and Expenses | 1 640 | 1 640 | 1 115 | 47% |
| Purchases of Goods and external expenses | 1810 | 1409 | 1647 | -14% |
| Salaries and social charges | 1 661 | 1 661 | 1 957 | -15% |
| Depreciation & Amortization | 102 | 102 | 103 | -1% |
| Allocations to provisions | 41 | 442 | 424 | -90% |
| Other expenses | 30 | |||
| Other operating expenses | 1 805 | 2 205 | 2 514 | -12% |
| Operating income | -2 987 | -3 665 | -3 179 | 15% |
| Financial result | 84 | 84 | -65 | 228% |
| Extraordinary result | 16 | 16 | 263 | -94% |
| Research tax credits | 525 | 525 | 504 | 4% |
| Net income | -2 363 | -3 043 | -2 476 | 23% |
| Average headcount (FTE) | 28 | 28 | 30 |
These accounts have been subject to a limited review by the auditors. (1)
Cash flow and going concern
As of December 31, 2024, Theraclion had a cash balance of €4.1 million, down from €5.9 million at end June 2024. This cash position will cover Theraclion's needs until the middle of the second quarter of 2025.
The Company has already taken steps to secure the financing it needs to pursue its strategy and begin its commercial expansion. Should the Company be unable to obtain such funding, its long-term viability could be at risk.
Next financial publication
Publication of the 2024 financial results on April 29, 2025.